Urinary Incontinence Drugs Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major urinary incontinence drugs markets are expected to exhibit a CAGR of 2.65% during 2024-2034.
The urinary incontinence drugs market has been comprehensively analyzed in IMARC's new report titled "Urinary Incontinence Drugs Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Urinary incontinence refers to the involuntary loss of bladder control, resulting in the unintentional leakage of urine. It is a common condition that can affect people of all ages, although it is more prevalent among older adults, particularly women. The most typical symptom associated with the ailment is urinary leakage, which can occur during activities like coughing, sneezing, laughing, physical exertion, etc. Various other indications include nocturia (frequent urination during the night), bedwetting, incomplete bladder emptying, etc. Individuals suffering from the ailment may also experience emotional distress, embarrassment, and a decreased quality of life due to the impact on daily activities and social interactions. Urinary incontinence drugs are medications used to treat and manage the symptoms associated with the condition. These are typically taken orally, but in some cases, they may be available in transdermal patches, topical gels, or other formulations. The choice of drug depends on various factors, including the type of incontinence, underlying cause, patient characteristics, potential side effects, etc. Urinary incontinence medications aim to improve bladder control, reduce urgency and frequency, and minimize urine leakage, thus enhancing the patient's quality of life.
The escalating cases of dysfunction of the pelvic floor muscles caused by childbirth, aging, hormonal changes, etc., are primarily driving the urinary incontinence drugs market. In addition to this, the rising prevalence of several associated risk factors, including urinary tract infections, overactive bladder, prostate issues, chronic coughing, neurological disorders, etc., is also bolstering the market growth. Furthermore, the inflating adoption of anticholinergic medications, such as oxybutynin and tolterodine, to help relax bladder muscles as well as reduce overactive bladder contractions is acting as another significant growth-inducing factor. Additionally, several key players are investing in extensive R&D activities to introduce new drugs that target the urothelial mucosa, ion channels, and neurotransmitter systems involved in bladder function. This, in turn, is also creating a positive outlook for the market. Besides this, the introduction of novel drug delivery systems, such as transdermal patches, intravesical instillations, subcutaneous or intramuscular injections, etc., to optimize drug delivery, improve patient compliance, and potentially minimize side effects, is expected to drive the urinary incontinence drugs market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the urinary incontinence drugs market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for urinary incontinence drugs and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the urinary incontinence drugs market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the urinary incontinence drugs market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the urinary incontinence drugs market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current urinary incontinence drugs marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the urinary incontinence drugs market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the urinary incontinence drugs market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the urinary incontinence drugs market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of urinary incontinence drugs across the seven major markets?
What is the number of prevalent cases (2018-2034) of urinary incontinence drugs by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of urinary incontinence drugs by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with urinary incontinence drugs across the seven major markets?
What is the size of the urinary incontinence drugs patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of urinary incontinence drugs?
What will be the growth rate of patients across the seven major markets?
Urinary Incontinence Drugs: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for urinary incontinence drugs drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the urinary incontinence drugs market?
What are the key regulatory events related to the urinary incontinence drugs market?
What is the structure of clinical trial landscape by status related to the urinary incontinence drugs market?
What is the structure of clinical trial landscape by phase related to the urinary incontinence drugs market?
What is the structure of clinical trial landscape by route of administration related to the urinary incontinence drugs market?
The urinary incontinence drugs market has been comprehensively analyzed in IMARC's new report titled "Urinary Incontinence Drugs Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Urinary incontinence refers to the involuntary loss of bladder control, resulting in the unintentional leakage of urine. It is a common condition that can affect people of all ages, although it is more prevalent among older adults, particularly women. The most typical symptom associated with the ailment is urinary leakage, which can occur during activities like coughing, sneezing, laughing, physical exertion, etc. Various other indications include nocturia (frequent urination during the night), bedwetting, incomplete bladder emptying, etc. Individuals suffering from the ailment may also experience emotional distress, embarrassment, and a decreased quality of life due to the impact on daily activities and social interactions. Urinary incontinence drugs are medications used to treat and manage the symptoms associated with the condition. These are typically taken orally, but in some cases, they may be available in transdermal patches, topical gels, or other formulations. The choice of drug depends on various factors, including the type of incontinence, underlying cause, patient characteristics, potential side effects, etc. Urinary incontinence medications aim to improve bladder control, reduce urgency and frequency, and minimize urine leakage, thus enhancing the patient's quality of life.
The escalating cases of dysfunction of the pelvic floor muscles caused by childbirth, aging, hormonal changes, etc., are primarily driving the urinary incontinence drugs market. In addition to this, the rising prevalence of several associated risk factors, including urinary tract infections, overactive bladder, prostate issues, chronic coughing, neurological disorders, etc., is also bolstering the market growth. Furthermore, the inflating adoption of anticholinergic medications, such as oxybutynin and tolterodine, to help relax bladder muscles as well as reduce overactive bladder contractions is acting as another significant growth-inducing factor. Additionally, several key players are investing in extensive R&D activities to introduce new drugs that target the urothelial mucosa, ion channels, and neurotransmitter systems involved in bladder function. This, in turn, is also creating a positive outlook for the market. Besides this, the introduction of novel drug delivery systems, such as transdermal patches, intravesical instillations, subcutaneous or intramuscular injections, etc., to optimize drug delivery, improve patient compliance, and potentially minimize side effects, is expected to drive the urinary incontinence drugs market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the urinary incontinence drugs market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for urinary incontinence drugs and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the urinary incontinence drugs market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the urinary incontinence drugs market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the urinary incontinence drugs market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current urinary incontinence drugs marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the urinary incontinence drugs market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the urinary incontinence drugs market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the urinary incontinence drugs market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of urinary incontinence drugs across the seven major markets?
What is the number of prevalent cases (2018-2034) of urinary incontinence drugs by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of urinary incontinence drugs by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with urinary incontinence drugs across the seven major markets?
What is the size of the urinary incontinence drugs patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of urinary incontinence drugs?
What will be the growth rate of patients across the seven major markets?
Urinary Incontinence Drugs: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for urinary incontinence drugs drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the urinary incontinence drugs market?
What are the key regulatory events related to the urinary incontinence drugs market?
What is the structure of clinical trial landscape by status related to the urinary incontinence drugs market?
What is the structure of clinical trial landscape by phase related to the urinary incontinence drugs market?
What is the structure of clinical trial landscape by route of administration related to the urinary incontinence drugs market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 URINARY INCONTINENCE DRUGS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 URINARY INCONTINENCE DRUGS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 URINARY INCONTINENCE DRUGS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 URINARY INCONTINENCE DRUGS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 URINARY INCONTINENCE DRUGS - UNMET NEEDS
10 URINARY INCONTINENCE DRUGS - KEY ENDPOINTS OF TREATMENT
11 URINARY INCONTINENCE DRUGS - MARKETED PRODUCTS
11.1 List of Urinary Incontinence Drugs Marketed Drugs Across the Top 7 Markets
11.1.1 Ditropan XL (Oxybutynin chloride) - ALZA
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Detrol (Tolterodine) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Myrbetriq (Mirabegron) - Astellas Pharma
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Toviaz (Fesoterodine) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Vesicare (Solifenacin) - Astellas Pharma
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 URINARY INCONTINENCE DRUGS - PIPELINE DRUGS
12.1 List of Urinary Incontinence Drugs Pipeline Drugs Across the Top 7 Markets
12.1.1 Litoxetine - IXALTIS
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 TAS303 - Taiho Pharmaceutical
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Autologous muscle-derived cells (AMDC) - Cook MyoSite
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. URINARY INCONTINENCE DRUGS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. URINARY INCONTINENCE DRUGS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 URINARY INCONTINENCE DRUGS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Urinary Incontinence Drugs - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Urinary Incontinence Drugs - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Urinary Incontinence Drugs - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Urinary Incontinence Drugs - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Urinary Incontinence Drugs - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Urinary Incontinence Drugs - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Urinary Incontinence Drugs - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Urinary Incontinence Drugs - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Urinary Incontinence Drugs - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Urinary Incontinence Drugs - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Urinary Incontinence Drugs - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Urinary Incontinence Drugs - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Urinary Incontinence Drugs - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Urinary Incontinence Drugs - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Urinary Incontinence Drugs - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Urinary Incontinence Drugs - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Urinary Incontinence Drugs - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Urinary Incontinence Drugs - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Urinary Incontinence Drugs - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Urinary Incontinence Drugs - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Urinary Incontinence Drugs - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Urinary Incontinence Drugs - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Urinary Incontinence Drugs - Access and Reimbursement Overview
16 URINARY INCONTINENCE DRUGS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 URINARY INCONTINENCE DRUGS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 URINARY INCONTINENCE DRUGS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 URINARY INCONTINENCE DRUGS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 URINARY INCONTINENCE DRUGS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 URINARY INCONTINENCE DRUGS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 URINARY INCONTINENCE DRUGS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 URINARY INCONTINENCE DRUGS - UNMET NEEDS
10 URINARY INCONTINENCE DRUGS - KEY ENDPOINTS OF TREATMENT
11 URINARY INCONTINENCE DRUGS - MARKETED PRODUCTS
11.1 List of Urinary Incontinence Drugs Marketed Drugs Across the Top 7 Markets
11.1.1 Ditropan XL (Oxybutynin chloride) - ALZA
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Detrol (Tolterodine) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Myrbetriq (Mirabegron) - Astellas Pharma
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Toviaz (Fesoterodine) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Vesicare (Solifenacin) - Astellas Pharma
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 URINARY INCONTINENCE DRUGS - PIPELINE DRUGS
12.1 List of Urinary Incontinence Drugs Pipeline Drugs Across the Top 7 Markets
12.1.1 Litoxetine - IXALTIS
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 TAS303 - Taiho Pharmaceutical
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Autologous muscle-derived cells (AMDC) - Cook MyoSite
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. URINARY INCONTINENCE DRUGS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. URINARY INCONTINENCE DRUGS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 URINARY INCONTINENCE DRUGS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Urinary Incontinence Drugs - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Urinary Incontinence Drugs - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Urinary Incontinence Drugs - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Urinary Incontinence Drugs - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Urinary Incontinence Drugs - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Urinary Incontinence Drugs - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Urinary Incontinence Drugs - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Urinary Incontinence Drugs - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Urinary Incontinence Drugs - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Urinary Incontinence Drugs - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Urinary Incontinence Drugs - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Urinary Incontinence Drugs - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Urinary Incontinence Drugs - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Urinary Incontinence Drugs - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Urinary Incontinence Drugs - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Urinary Incontinence Drugs - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Urinary Incontinence Drugs - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Urinary Incontinence Drugs - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Urinary Incontinence Drugs - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Urinary Incontinence Drugs - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Urinary Incontinence Drugs - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Urinary Incontinence Drugs - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Urinary Incontinence Drugs - Access and Reimbursement Overview
16 URINARY INCONTINENCE DRUGS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 URINARY INCONTINENCE DRUGS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 URINARY INCONTINENCE DRUGS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
